Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5272098 | 0.84 | PPARG (0.49) | PPARGRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL30116328 | 0.84 | PPARG (0.49) | PPARGRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL6967623 | 0.82 | PPARG (0.47) | PPARGRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL667777 | 0.82 | PPARG (0.51) | PPARGRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL10794557 | 0.82 | TDP1 (0.40) | LMNAGAAATMTDP1BCHE | |
| SCHEMBL18697298 | 0.82 | PPARG (0.47) | PPARGRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL1577432 | 0.81 | PTGS2 (0.52) | PPARGRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL17593430 | 0.81 | RXRA (0.50) | PPARGRXRARXRBRXRGMRGPRX4 | |
| SCHEMBL4254573 | 0.81 | TDP1 (0.46) | RXRARXRBRXRGGAAATM | |
| SCHEMBL2884826 | 0.81 | TDP1 (0.58) | RXRARXRBRXRGGAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919508-B2 | 3-piperidinylisochroman-5-ols as dopamine agonists | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919508-B2 | 3-piperidinylisochroman-5-ols as dopamine agonists | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1749001-B1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMA INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2035435-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2024380-A2 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | Adenosine Therapeutics, LLC (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007139569-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007136817-A2 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADENOSINE THERAPEUTICS, LLC (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-0404876-A4 | LONG-CHAIN ALIPHATIC HYDROCARBYL AMINE ADDITIVES HAVING AN OXY-CARBONYL CONNECTING GROUP | — | 1991-04-24 | — | — | EP | disclosed |
| EP-0404876-A1 | LONG-CHAIN ALIPHATIC HYDROCARBYL AMINE ADDITIVES HAVING AN OXY-CARBONYL CONNECTING GROUP. | CHEVRON RES (US) | 1991-01-02 | — | — | EP | disclosed |
| WO-1990002785-A1 | LONG-CHAIN ALIPHATIC HYDROCARBYL AMINE ADDITIVES HAVING AN OXY-CARBONYL CONNECTING GROUP | CHEVRON RESEARCH COMPANY (US) | 1990-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | DRD3, DRD2, DRD4 | PPARG 2157/4885RXRA 2410/4885RXRB 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.